Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM63YS
|
|||
| Drug Name |
AZD8871
|
|||
| Synonyms |
Navafenterol; AZD-8871; AZD8871; Navafenterol [USAN]; LAS191351; LAS-191351; U29GY32XJ4; UNII-U29GY32XJ4; Azd 8871; 1435519-06-4; WHO 11100; 2-Thiopheneacetic acid, alpha-hydroxy-alpha-2-thienyl-, trans-4-((3-(5-((((2R)-2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl)amino)methyl)-1H-benzotriazol-1-yl)propyl)methylamino)cyclohexyl ester; NAVAFENTEROL [INN]; CHEMBL4297483; SCHEMBL16429536; SCHEMBL22766780; AZD 8871 [WHO-DD]; EX-A7799; BDBM50528210; AKOS040750679; HY-120802; CS-0079218; 2-THIOPHENEACETIC ACID, .ALPHA.-HYDROXY-.ALPHA.-2-THIENYL-, TRANS-4-((3-(5-((((2R)-2-(1,2-DIHYDRO-8-HYDROXY-2-OXO-5-QUINOLINYL)-2-HYDROXYETHYL)AMINO)METHYL)-1H-BENZOTRIAZOL-1-YL)PROPYL)METHYLAMINO)CYCLOHEXYL ESTER; TRANS-4-((3-(5-((((2R)-2-HYDROXY-2-(8-HYDROXY-2-OXO-1,2-DIHYDRO-5- QUINOLINYL)ETHYL)AMINO)METHYL)-1H-BENZOTRIAZOL-1-YL)PROPYL)(METHYL)AMINO)CYCLOHEXYL HYDROXY(DI-2-THIENYL)ACETATE
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J40-J44, J47; ICD-9: 490-492, 494-496] | Phase 2 | [1] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C38H42N6O6S2
|
|||
| Canonical SMILES |
CN(CCCN1C2=C(C=C(C=C2)CNCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)N=N1)C5CCC(CC5)OC(=O)C(C6=CC=CS6)(C7=CC=CS7)O
|
|||
| InChI |
InChI=1S/C38H42N6O6S2/c1-43(25-8-10-26(11-9-25)50-37(48)38(49,33-5-2-19-51-33)34-6-3-20-52-34)17-4-18-44-30-14-7-24(21-29(30)41-42-44)22-39-23-32(46)27-12-15-31(45)36-28(27)13-16-35(47)40-36/h2-3,5-7,12-16,19-21,25-26,32,39,45-46,49H,4,8-11,17-18,22-23H2,1H3,(H,40,47)/t25?,26?,32-/m0/s1
|
|||
| InChIKey |
ZNKWRAKPQQZLNX-FFJARJNZSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03645434) A Phase IIa, Randomised, Multi-centre, Double-blind, Placebo and Active-controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871 Administered Once Daily for 2 Weeks in Patients With Moderate to Severe COPD. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.